Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Insight Molecular Diagnostics Inc. (IMDX : NSDQ)

• Company Description    Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. Number of Employees: 49

• Price / Volume Information    Yesterday's Closing Price: $3.08 Daily Weekly Monthly 20 Day Moving Average: 30,237 shares Shares Outstanding: 28.62 (millions) Market Capitalization: $88.15 (millions) Beta: 1.10 52 Week High: $4.75 52 Week Low: $1.92 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 28.33% 26.08% 12 Week -2.53% -11.46% Year To Date 29.41% 19.30%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 INTERNATIONAL PLAZA DR. SUITE 510 - NASHVILLE,TN 37217 USA ph: 949-409-7600 fax: 510-521-3389 dfarrell@lifesciadvisors.com https://investors.imdxinc.com

• General Corporate Information    Officers Joshua Riggs - President and Chief Executive Officer and Director James Liu - Vice President Accounting; Controller; Treasurer a Andrea James - Chief Financial Officer Andrew Arno - Director Andrew J. Last - Director Peer Information Insight Molecular Diagnostics Inc. (HLIS) Insight Molecular Diagnostics Inc. (AZTA) Insight Molecular Diagnostics Inc. (APYI) Insight Molecular Diagnostics Inc. (RNVA) Insight Molecular Diagnostics Inc. (HMSY) Insight Molecular Diagnostics Inc. (LRSI) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MEDICAL INFO SYS Sector: Medical CUSIP: 68235C206 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 28.62 Most Recent Split Date: 7.00 (0.05:1) Beta: 1.10 Market Capitalization: $88.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 80.22 Price/Cash Flow: - Price / Sales: 20.71 EPS Growth vs. Year Ago Period: 16.67% vs. Previous Quarter: -15.38% Sales Growth vs. Year Ago Period: 398.08% vs. Previous Quarter: -75.77% ROE 06/30/25 - -983.30 03/31/25 - -215.59 12/31/24 - -239.86 ROA 06/30/25 - -39.81 03/31/25 - -27.23 12/31/24 - -30.32 Current Ratio 06/30/25 - 4.04 03/31/25 - 3.74 12/31/24 - 1.62 Quick Ratio 06/30/25 - 3.93 03/31/25 - 3.70 12/31/24 - 1.56 Operating Margin 06/30/25 - -505.45 03/31/25 - -425.76 12/31/24 - -1,011.48 Net Margin 06/30/25 - -1,489.71 03/31/25 - -1,516.06 12/31/24 - -3,239.02 Pre-Tax Margin 06/30/25 - -1,489.71 03/31/25 - -1,514.57 12/31/24 - -3,225.04 Book Value 06/30/25 - 0.04 03/31/25 - 0.36 12/31/24 - -0.70 Inventory Turnover 06/30/25 - 4.32 03/31/25 - 6.62 12/31/24 - 7.11 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.20 12/31/24 - - Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 16.87 12/31/24 - -

Powered by Zacks Investment Research ©